International journal of obesity (2005)

Semaglutide under the skin and its link to weight loss and inflammation in overweight adults without diabetes

Updated

Abstract

Subcutaneous semaglutide is associated with significant weight loss and improvements in cardiometabolic risk factors.

  • Obesity is a chronic condition linked to several serious health issues.
  • Semaglutide has proven to be an effective medication for managing obesity.
  • The review focused on adults with overweight or obesity who do not have diabetes.
  • Efficacy and safety of semaglutide were assessed through systematic review and meta-analysis.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free